Jordan Gauthier, MD, MSc, discusses the rationale for combining ibrutinib with CD19-targeting chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.
Jordan Gauthier, MD, a senior clinical research fellow at Fred Hutchinson Cancer Research Center, discusses the rationale for combining ibrutinib (Imbruvica) with CD19-targeting chimeric antigen receptor (CAR) T cells for the treatment of patients with chronic lymphocytic leukemia (CLL).
While CAR T cells have been successful in aggressive lymphomas, acute lymphocytic leukemia, and non-Hodgkin lymphoma, the results have not been as good in CLL, Gauthier says. However, ibrutinib can be beneficial by helping CLL cells migrate from the lymph nodes to the peripheral blood and can help improve the functionality of the CAR T cells.
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More